Nice Quarter from A...
Health Care: Drugs
Regeneron Pharmaceuticals Inc. (REGN: NASDAQ)
$102.70 2.36 | 2.35%
02/08/12 - 04:00 PM ET
1.40M / 1.37M
Vol / Avg. Vol:100.73 / 100.34
Open / Prev. Close:98.59 - 102.86
Today's Range:34.05 - 101.93
52 Wk Range:81.02%
Performance YTD:TheStreet Rating:
Portfolios with REGN
- Portfolio NameUser Type
- Contributor6 Drug Stocks Unworthy of B...
- ContributorStocks At New 52-Week Highs...
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- ContributorPharma Short Squeezes for 2011
- Userbiotech
- ProQVT Financial
- ContributorBarron's Insider Purchases ...
- ProT. Rowe Price New Horizons ...
- UserASCO 2010 Part 2
Latest REGN Headlines from TheStreet
- Tuesday's Top 10 Articles, Videos on TheStreet 02.07.12 | 01:02 pm
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 6 Stocks at New 52-Week Highs 01.27.12 | 02:01 pm
- Insiders Trading CBRL, TJX, SPB 01.17.12 | 08:01 am
- Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
- 3 Stocks I Saw on TV, January 11
01.11.12 | 07:01 am - Regeneron Pharmaceuticals' CEO Presents At The JPMorgan Global Healthcare Conference (Transcript) 01.09.12 | 10:01 pm
- Dendreon: Provenge Q4 Sales Beat 01.05.12 | 10:01 am
- Biotech Buyside Predictions for 2012 01.05.12 | 09:01 am
- Biotech 2012 Kickoff Party: Investor Preview 01.04.12 | 11:01 am
Press Releases for REGN
- Two Year Results Of Phase 3 Studies With EYLEA⢠(aflibercept) Injection In Wet AMD Show Sustained Improvement In Visual Acuity - PR Newswire 12.05.11 | 02:12 am
- Regeneron And Bayer Initiate Phase 3 Clinical Program For The Treatment Of Wet Age-Related Macular Degeneration In China - PR Newswire 11.28.11 | 02:11 am
- Phase 3 Trial Of ZALTRAP⢠(aflibercept) In Advanced Prostate Cancer To Continue As Planned At Recommendation Of Independent Data Monitoring Committee - PR Newswire 07.07.11 | 07:07 am
- EYLEA⢠(aflibercept Injection) Submitted In Japan For Marketing Authorization For The Treatment Of Wet Age-Related Macular Degeneration - PR Newswire 06.28.11 | 11:06 pm
- VEGF Trap-Eye Submitted For EU Marketing Authorization For Treatment Of Wet Age-Related Macular Degeneration - PR Newswire 06.07.11 | 02:06 am
- ZALTRAP⢠(aflibercept) Significantly Improved Survival In Previously Treated Metastatic Colorectal Cancer Patients - PR Newswire 06.06.11 | 01:06 am
- Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion - PR Newswire 04.27.11 | 04:04 pm
- Sanofi-aventis And Regeneron Report Positive Phase III Results With ZALTRAP⢠(aflibercept) In Second-line Metastatic Colorectal Cancer - PR Newswire 04.26.11 | 04:04 pm
- Regeneron And Bayer Announce Start Of Phase 3 Clinical Program In Diabetic Macular Edema - PR Newswire 04.08.11 | 02:04 am
- BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals For 131,000 Square Feet At Landmark - PR Newswire 12.03.09 | 07:12 pm
Partner Headlines for REGN
- REGN Projects Strong Q4 Eylea Sales - Analyst Blog - Zacks 01.13.12 | 06:01 pm
- Biotech Stocks On A Tear: I Like Celgene - Seeking Alpha 01.13.12 | 09:01 am
- Biotech Investors Buoyed By Signs Of Speedier Drug Launches - Seeking Alpha 01.09.12 | 08:01 am
- Cramer's Mad Money - 9 Things To Look For In The Coming Week (1/6/12) - Seeking Alpha 01.08.12 | 06:01 am
- End-of-Day Market Summary for January 6, 2012 - Benzinga 01.06.12 | 04:01 pm
- Benzinga's Volume Gainers - Benzinga 01.06.12 | 01:01 pm
- Company News for December 6, 2011 - Corporate Summary - Zacks 12.06.11 | 10:12 am
- Brean Murray Lowers PT on Regeneron Pharma to $67 - Benzinga 12.05.11 | 09:12 am
- Regeneron/Bayer Initiate Study - Analyst Blog - Zacks 11.28.11 | 09:11 am
- Regeneron Announces FDA Approval of EYLEA Injection for Treatment of Wet Age-Related Macular Degeneration - Benzinga 11.18.11 | 06:11 pm
